Jiaxing Andicon Biotech Co., Ltd. announced that it has received over CNY 200 million in round of funding co-led by new investors Simcere Pharmaceutical Group Limited, Huajin Investments Limited and Huajin Avenue Investment Co., Ltd on June 25, 2024. The transaction included the participation from new investors Jiaxing Jiarui Future Star Equity Investment Partnership Ent. (L.P.), a fund managed by Jiaxing Jiarui Investment Management Co., Ltd., Jinshajiang United Runpu Medical Fund, Shanghai Wenzhou Investment Management Co., Ltd., Songze Capital and Shenzhen Jieshun Health Management Consulting Co., Ltd., returning investors Shenzhen Co-win Venture Capital Investments Limited and Jiaxing Nanhu District Xinchuang Venture Capital Co., Ltd.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.73 HKD | -0.69% | +1.06% | -14.86% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.86% | 1.86B | |
+20.76% | 43.77B | |
+28.00% | 22.83B | |
+20.25% | 15.56B | |
+18.82% | 14.34B | |
+55.83% | 12.96B | |
-0.05% | 6.79B | |
-12.70% | 6.41B | |
-8.87% | 5.73B | |
+14.65% | 5.69B |
- Stock Market
- Equities
- 2096 Stock
- News Simcere Pharmaceutical Group Limited
- Jiaxing Andicon Biotech Co., Ltd. announced that it has received CNY 200 million in funding from a group of investors